- Home
- RILYP vs BCTXL Comparison
RILYP vs BCTXL Comparison
Compare RILYP & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RILYP | BCTXL |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | Canada |
| Employees | 2056 | 4 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RILYP | BCTXL |
|---|---|---|
| Price | $10.71 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 31.9K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $0.90 |
| 52 Week High | $14.50 | $1.40 |
Technical Indicators
Market Signals| Indicator | RILYP | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 49.43 |
| Support Level | $8.56 | $0.92 |
| Resistance Level | $11.47 | $1.25 |
| Average True Range (ATR) | 0.91 | 0.09 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 75.32 | 40.62 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About BCTXL BriaCell Therapeutics Corp. Warrant expiring 2031
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.